NASDAQ:ARAV Aravive (ARAV) Stock Price, News & Analysis $0.04 0.00 (0.00%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$0.04▼$0.0450-Day Range$0.04▼$0.0452-Week Range$0.04▼$2.46VolumeN/AAverage VolumeN/AMarket Capitalization$2.95 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsSustainabilityTrends Get Aravive alerts: Email Address Ad Porter & CompanyWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…You must read this new presentation from Porter Stansberry. About Aravive Stock (NASDAQ:ARAV)Aravive, Inc., a clinical-stage biopharmaceutical company, develops transformative treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of platinum- resistant recurrent ovarian cancer; and in Phase Ib/II clinical trial for the treatment of clear cell renal cell carcinoma and pancreatic adenocarcinoma. The company also develops AVB-S6, a soluble Fc-fusion protein to block the activation of the GAS6-AXL signaling pathway. It has a license and collaboration agreement with WuXi Biologics (Hong Kong) Limited to identify and develop novel high-affinity bispecific antibodies targeting cancer and fibrosis; and license agreement with 3D Medicines Inc. to develop products that contain batiraxcept as the sole drug substance for the treatment of human oncological diseases in mainland China, Taiwan, Hong Kong, and Macau. The company was formerly known as Versartis, Inc. and changed its name to Aravive, Inc. in October 2018. Aravive, Inc. was incorporated in 2008 and is headquartered in Houston, Texas.Read More ARAV Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ARAV Stock News HeadlinesApril 23, 2024 | finance.yahoo.comPharmaEssentia Appoints Robert Geller, M.D. as Head of Medical and Shawn Gibbs, J.D. as Head of LegalApril 2, 2024 | finance.yahoo.comDiabetic Kidney Disease Market to Witness Upsurge in Growth at a CAGR of ~6.5% by 2034 | DelveInsightJuly 26, 2024 | Behind the Markets (Ad)Rare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED will cut rates any day now. But there's one indicator that's flashing a BIG warning sign to investors.January 30, 2024 | finance.yahoo.comTelo Genomics Engages US Diagnostics Experts to Power Product Adoption in the USJanuary 18, 2024 | msn.comCrude Oil Rises Over 1%; Processa Pharmaceuticals Shares SlideJanuary 18, 2024 | msn.comWhy Is Nuvve (NVVE) Stock Down 31% Today?January 18, 2024 | markets.businessinsider.comWhy Is Aravive (ARAV) Stock Down 52% Today?January 17, 2024 | marketwatch.comAravive Shares Drop 53%, Company to Delist and Deregister StockJuly 26, 2024 | Behind the Markets (Ad)Rare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED will cut rates any day now. But there's one indicator that's flashing a BIG warning sign to investors.January 17, 2024 | finance.yahoo.comAravive, Inc. to Delist from The Nasdaq Stock MarketDecember 27, 2023 | benzinga.comAravive Stock (NASDAQ:ARAV), Short Interest ReportDecember 27, 2023 | benzinga.comAravive Stock (NASDAQ:ARAV) Dividends: History, Yield and DatesDecember 8, 2023 | bizjournals.comHouston is building it. Why won't they come?November 20, 2023 | bizjournals.comHouston companies, universities win nearly $50.7 million in latest CPRIT awardsNovember 12, 2023 | morningstar.comAravive Inc ARAVOctober 13, 2023 | finance.yahoo.comAravive (ARAV) Upgraded to Strong Buy: What Does It Mean for the Stock?September 24, 2023 | finance.yahoo.comAravive, Inc. (ARAV) Stock Historical Prices & Data - Yahoo FinanceAugust 29, 2023 | benzinga.comThinking about buying stock in Limbach Holdings, Aravive, Up Fintech Holding, YS Biopharma, or Big Lots?See More Headlines Receive ARAV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aravive and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings10/27/2021Today7/26/2024Next Earnings (Estimated)8/19/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ARAV CUSIPN/A CIK1513818 Webwww.aravive.com Phone(936) 355-1910FaxN/AEmployees23Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$9.14 million Price / Sales0.32 Cash FlowN/A Price / Cash FlowN/A Book Value$0.18 per share Price / Book0.22Miscellaneous Outstanding Shares73,560,000Free Float29,131,000Market Cap$2.95 million OptionableOptionable Beta2.12 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesDr. Fredric N. Eshelman Pharm.D. (Age 75)Executive Chairman Comp: $95kDr. Jeffrey L. Cleland Ph.D. (Age 59)Co-Founder Comp: $669.98kDr. Joshua Aaron Silverman Ph.D.Co-FounderMr. Marek Ciszewski J.D.Vice President of Investor RelationsKey CompetitorsImunonNASDAQ:IMNNVaccinexNASDAQ:VCNXTraws PharmaNASDAQ:TRAWMonopar TherapeuticsNASDAQ:MNPREterna TherapeuticsNASDAQ:ERNAView All Competitors ARAV Stock Analysis - Frequently Asked Questions How have ARAV shares performed this year? Aravive's stock was trading at $0.1237 at the start of the year. Since then, ARAV stock has decreased by 67.6% and is now trading at $0.0401. View the best growth stocks for 2024 here. How were Aravive's earnings last quarter? Aravive, Inc. (NASDAQ:ARAV) posted its quarterly earnings results on Wednesday, October, 27th. The company reported ($0.53) EPS for the quarter, missing analysts' consensus estimates of ($0.46) by $0.07. The firm earned $2.41 million during the quarter, compared to analyst estimates of $2.36 million. How do I buy shares of Aravive? Shares of ARAV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Aravive own? Based on aggregate information from My MarketBeat watchlists, some other companies that Aravive investors own include Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), SCYNEXIS (SCYX), VBI Vaccines (VBIV), Applied Genetic Technologies (AGTC), Flexion Therapeutics (FLXN) and Inovio Pharmaceuticals (INO). This page (NASDAQ:ARAV) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aravive, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aravive With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ARAV Stock Alerts